Despite some limitations, as previously reported [14], to the best of our knowledge, this is the first study providing data on the immunological pattern of anti-Dsg3 and anti-Dsg1 Ab, and of leucocyte subsets, in a sample of PV patients with oral involvement, treated with RTX as an adjuvant. This evidence concerns the gene DSG3 and acquired polycythemia vera.